Newly discovered biomarkers could improve endometrial cancer treatment

Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose better treatments for patients with recurrent endometrial cancer. Their study, published in the Journal for ImmunoTherapy of Cancer, found specific proteins in the blood (biomarkers) that may predict how well a patient will respond to a combination of two cancer drugs, cabozantinib and nivolumab.